急性白血病患者血清sICAM-1水平变化及其临床意义

Clinical study on the level of serum sICAM-1 in acute leukemia

目的:观察与探讨急性白血病患者血清可溶性细胞间粘附分子-1(sICAM-1)水平的变化及其与病情,疗效的关系。方法:ELISA法对20例正常健康人及20例急性淋巴细胞白血病(ALL)、27例急性髓性白血病(AML)化疗前后血清sICAM-1水平进行检测。结果:ALL组、AML组sICAM-1水平(ng/ml)均显著高于正常对照组(444.5±159.4,448.5±160.6,Vs 306.2±93.9)(P<0.01)。化疗后完全缓解(CR)组sICAM-1水平与正常对照组无差异(P>0.05)。而ALL、AML未CR组化疗前sICAM-1水平显著高于CR组化疗前水平(P<0.01)。结论:血清sICAM-1水平可作为观察疗效,判断预后的重要指标之一。

Objective： To investigate the level of serum soluble ICAM-I（sICAM-1） in acute leukemia and the correlation with clinical features and treatment effect. Methods： The level of sICAM-1 in ALL group （n= 20）, AML group（n=27） and the control group（n=20） was measured by ELISA. Results： The levels of sICAM- 1 that in ALL group and AML group were higher than that in the control group. When patients reached com- plete remission （CR）, the level of sICAM-1 fell to the normal level and the unremission group had higher level of sICAM- 1 （ng/ml） than the CR group before chemotherapy（444.5±159.4,448.5±160.6, Vs 306.2±93.9） （P〈0.01）. Conclusion： The level of sICAM-1 in acute leukemia is related to treatment effect and prognosis.